13 results on '"Liquid chromatography–mass spectrometry"'
Search Results
2. Development and validation of a bioanalytical method for quantification of LNA-i-miR-221, a 13-mer oligonucleotide, in rat plasma using LC–MS/MS.
- Author
-
Franzoni, S., Vezzelli, A., Turtoro, A., Solazzo, L., Greco, A., Tassone, P., Di Martino, M.T., and Breda, M.
- Subjects
- *
DRUG development , *BLOOD plasma , *MICRORNA , *OLIGONUCLEOTIDES , *ANALYTICAL chemistry , *LABORATORY rats , *LIQUID chromatography-mass spectrometry - Abstract
LNA-i-miR-221, a 13-mer oligonucleotide, is a new miR-221 inhibitor that could be used as a novel drug for multiple myeloma. Herein, an ion-pair reversed phase liquid chromatography–tandem mass spectrometry (LC–MS/MS) method has been developed and validated for the quantification of LNA-i-miR-221 in rat plasma. Plasma samples were prepared with an initial phenol/chloroform/isoamyl alcohol liquid–liquid extraction followed by a solid phase extraction. Chromatographic separation was performed with a gradient system on a HALO C18 column using hexafluoro-2-propanol/triethylamine buffer and methanol as mobile phase at a flow rate of 0.4 mL/min. Under these conditions LNA-i-miR-221 and the analogue internal standard are co-eluted at 1.2 min. The detection was carried out in multiple reaction monitoring (MRM) mode using a negative electrospray ionization (ESI) interface. The assay showed a good linearity within the calibration range 10–10000 ng/mL. The precision, accuracy, and recovery values were found to be <15% (<20% at LLOQ), 100 ± 15%, and 97.6–103.7%, respectively. This method was successfully applied to measure the concentrations of LNA-i-miR-221 in plasma samples following the intravenous administration during a 4-week toxicity study in rats. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. Simultaneous determination and pharmacokinetics of fourteen bioactive compounds in rat plasma by LC-ESI-MS/MS following intravenous injection of Gegen-Sanqi compatibility solution.
- Author
-
Ji, Bin, Zhao, Xing, Yu, Peipei, Meng, Lin, Zhao, Yunli, and Yu, Zhiguo
- Subjects
- *
BIOACTIVE compounds , *PHARMACOKINETICS , *BLOOD plasma , *BIOCOMPATIBILITY , *INTRAVENOUS injections , *LIQUID chromatography-mass spectrometry , *LABORATORY rats - Abstract
A high-performance liquid chromatography tandem mass spectrometry (HPLC–MS/MS) method was developed and fully validated for simultaneous determination of puerarin, 3′-hydroxy puerarin, 6″- O -xylosyl puerarin, 3′-methoxy puerarin, mirificin, puerarin-7- O -glucoside, daidzin, daidzein, daidzein-7- O -glucoside, ginsenoside-Rd, notoginsenoside-R1, ginsenoside-Re, ginsenoside-Rg1, ginsenoside-Rb1 in rat plasma after intravenous injection of 5 mL/kg Gegen-Sanqi compatibility solution (containing Pueraria flavonid 10.8 mg/mL and Panax notoginsenosidum 5.4 mg/mL). After addition of internal standard (IS) baicalin, the analytes and IS were recovered from rat plasma by protein precipitation using acetonitrile containing 0.1% formic acid. Chromatographic separation was performed on a Capcell pak MG C18 column (3.0 mm × 75 mm, 3.0 μm) at 35 °C with a flow rate of 0.75 mL/min. Mass spectrometry was conducted using multiple reaction monitoring in positive mode. The method was linear for all of the analytes over 1000 times concentration range with correlation coefficients greater than 0.99. The precision and accuracy of the LC–MS/MS assay based on the three analytical quality control (QC) levels were well within the acceptance criteria from FDA guidance for bioanalytical method validation. Method recoveries were higher than 75% and the matrix effects were minimal. All analytes were stable under tested conditions. It was the first time to study the pharmacokinetics of daidzein-7- O -glucoside in rat plasma. To the best of our knowledge, this is the first study for simultaneous determination of so many analytes in rat plasma after intravenous injection of Gegen-Sanqi compatibility solution. It was expected that the present work would provide some helpful references for the apprehension of the mechanism of action and further clinical efficacy studies of Gegen-Sanqi herb-pair. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Development of an LC–MS/MS method for the quantitation of deoxyglycychloxazol in rat plasma and its application in pharmacokinetic study.
- Author
-
Li, Rongshan, Ran, Ruixue, Li, Quansheng, Huang, Yurong, Gu, Yuan, and Si, Duanyun
- Subjects
ANTI-inflammatory agents ,PHARMACOKINETICS ,LIQUID chromatography-mass spectrometry ,ORAL medication ,LABORATORY rats - Abstract
Deoxyglycychloxazol (TY501) is a glycyrrhetinic acid derivative which exhibits high anti-inflammatory activity and reduced pseudoaldosteronism compared to glycyrrhetinic acid. In this study, a sensitive and rapid liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was established for the quantitation of TY501 in rat plasma. Plasma samples were treated by precipitating protein with methanol and supernatants were separated by a Symmetry C 8 column with the mobile phase consisting of methanol and 10 mM ammonium formate (containing 0.1% of formic acid) (90:10, v/v). The selected reaction monitoring (SRM) transitions were performed at m/z 647.4→191.2 for TY501 and m/z 473.3→143.3 for astragaloside aglycone (IS) in the positive ion mode with atmospheric pressure chemical ionization (APCI) source. Calibration curve was linear over the concentration range of 5–5000 ng/mL. The lower limit of quantification was 5 ng/mL. The mean recovery was over 88%. The intra- and inter-day precisions were lower than 6.0% and 12.8%, respectively, and the accuracy was within ±1.3%. TY501 was stable under usual storage conditions and handling procedure. The validated method has been successfully applied to a pharmacokinetic study after oral administration of TY501 to rats at a dosage of 10 mg/kg. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
5. A LC–MS/MS method for the determination of stachyose in rat plasma and its application to a pharmacokinetic study.
- Author
-
Zhou, Yang, Xu, De-sheng, Liu, Li, Qiu, Fu-rong, Chen, Jiong-liang, and Xu, Guang-lin
- Subjects
- *
STACHYOSE , *LIQUID chromatography-mass spectrometry , *BLOOD plasma , *PHARMACOKINETICS , *ACETONITRILE , *LABORATORY rats - Abstract
A sensitive, simple and rapid analytical method based on a liquid chromatography–tandem mass spetrometry (LC–MS/MS) has been established and validated for the determination of stachyose in rat plasma. Plasma samples were prepared by protein precipitation with acetonitrile. Separation of stachyose and nystose (internal standard, IS) was achieved using acetonitrile-water (55:45, v/v) as the mobile phase at a flow rate of 1 ml/min for 6 min on an Asahipak NH 2 P-50 4E column with an Asahipak NH2P-50G 4A guard column. Detection and quantification were conducted by LC–MS/MS method in the negative ion mode using multiple reaction monitoring (MRM) transitions at m / z [M–H] − 665.4 → 383.1 for stachyose and 665.5 → 485.0 for IS, respectively. The method was linear over the concentration ranges of 100–30000 ng/ml with a lower limit of quantification (LLOQ) of 100 ng/ml. The intra- and inter- day precision were all within 8.7% and the accuracy ranged from 97.2–108.4% and 98.3–102.4%, respectively. Stability studies indicated that stachyose was stable under short-term, long-term and three freeze-thaw storage conditions. The method was successfully applied to a pharmacokinetic study involving pulmonary administration of micronized Rehmannia glutinosa oligosaccharides (RGOS) to rats. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Simultaneous determination of 3-O-acetyloleanolic acid and oleanolic acid in rat plasma using liquid chromatography coupled to tandem mass spectrometry.
- Author
-
Kim, Eunyoung, Noh, Keumhan, Lee, Sang Joon, Shin, Beomsoo, Hwang, Joo Tae, Lee, Seung Woong, Rho, Mun-Chul, and Kang, Wonku
- Subjects
- *
LABORATORY rats , *BLOOD plasma , *LIQUID chromatography-mass spectrometry , *LIQUID-liquid extraction , *INTRAVENOUS drug abuse - Abstract
3- O -Acetyloleanolic acid (OAA) is a triterpenoid compound, and exerts an apoptosis in cancer cell lines, an inhibition of both atopic and allergic contact dermatitis in murine model, and a suppression of inflammatory bone loss in mice. OAA can be converted into oleanolic acid (OA) by hydrolysis in vivo , and OA exhibits several pharmacological effects as well. A liquid chromatographic method using tandem mass spectrometry (MS/MS) was developed for the simultaneous determination of OAA and OA in rat plasma. After liquid–liquid extraction with ethylacetate, both substances were chromatographed on a reversed phase column with a mobile phase of 0.1% formic acid aqueous solution and acetonitrile (1:9, v/v). The accuracy and precision of the assay were in accordance with FDA regulations for the validation of bioanalytical methods. This analytical method was successfully applied to monitor plasma concentrations of both substances over time following an intravenous administration of OAA in rats. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
7. Validated LC--MS/MS method for determination of YH-8, a novel PKnB inhibitor, in rat plasma and its application to pharmacokinetic study.
- Author
-
Zhai, Qianqian, Pang, Jing, Li, Guoqing, Li, Congran, Yang, Xinyi, Yu, Liyan, Wang, Yucheng, Li, Jian, and You, Xuefu
- Subjects
LIQUID chromatography-mass spectrometry ,PROTEIN kinase inhibitors ,BLOOD plasma ,PHARMACOKINETICS ,LABORATORY rats ,LIQUID-liquid extraction - Abstract
( E )-Methyl-4-aryl-4-oxabut-2-enoate (YH-8) is a novel PKnB protein kinase inhibitor with good anti-tuberculosis activity. To evaluate its pharmacokinetics in rats, a sensitive and selective high performance liquid chromatography–tandem mass spectrometric (LC--MS/MS) method has been developed and validated for the quantification of YH-8 in rat plasma for the first time. Samples were pre-treated using a liquid--liquid extraction with ethyl acetate and the chromatographic separation was performed on a C18 column by gradient elution with methanol--water as the mobile phase. YH-8 was detected using a tandem mass spectrometer in positive selected reaction monitoring (SRM) mode. Method validation revealed good linearity over the range of 1–500 ng/mL for YH-8 with a lower limit of quantification (LLOQ) of 1 ng/mL. Intra- and inter-day precision of YH-8 assay in rat plasma samples were 2.0%–6.8%, with accuracy of the method being 100.69%–106.18%. Stability test showed that when spiked into rat plasma, YH-8 was stable for 12 h at room temperature, for up to 15 days at −70 °C, and after three freeze-thaw cycles. Extracted samples were found to be stable over 12 h in an auto-sampler. The method was successfully applied to the pharmacokinetic study of YH-8 in rats after oral administration at 100 mg/kg and 200 mg/kg. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Determination of isobavachalcone in rat plasma by LC–MS/MS and its application to a pharmacokinetic study.
- Author
-
Ma, Tao, Nie, Li-Juan, Li, Hong-Mei, Huo, Qiang, Zhang, Yu-Xin, and Wu, Cheng-Zhu
- Subjects
- *
CHALCONE , *LABORATORY rats , *BLOOD plasma , *LIQUID chromatography-mass spectrometry , *PHARMACOKINETICS - Abstract
A simple and selective specific high-performance liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for determination of isobavachalcone (IBC) in rat plasma was developed. Neobavaisoflavone was used as an internal standard (IS). After protein precipitation with acetonitrile (2:1, v/v), the analyte and IS were separated on a 2.6 μm Kinetex C 18 column (100 mm × 2.1 mm i.d., Phenomenex) by isocratic elution with acetonitrile:water (60:40, v/v) as the mobile phase at a flow rate of 0.2 mL/min. An electrospray ionization (ESI) source was applied and operated in the negative ion mode; multiple reactions monitoring (MRM) mode was used for quantification, and the target fragment ions m / z 323.0 → 118.9 for IBC and m / z 321.1 → 265.0 for the IS were chosen. Good linearity was observed in the concentration range of 3.79–484.5 ng/mL for IBC in rat plasma. The recovery of IBC in plasma was in the range of 81.2–89.8%. Intra-day and inter-day precision were both lower than 10%. This method was suitable for pharmacokinetic studies after oral administration of 80 mg/kg IBC in rats. We also obtained pharmacokinetic parameters and concentration–time profiles for IBC after oral administration of IBC in rats. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
9. Development and validation of a liquid chromatography–tandem mass spectroscopy method for simultaneous determination of (+)-(13aS)-deoxytylophorinine and its pharmacologically active 3-O-desmethyl metabolite in rat plasma.
- Author
-
Yu, Feifei, Lv, Haining, Dong, Wujun, Ye, Jun, Hao, Huazhen, Ma, Shuanggang, Yu, Shishan, and Liu, Yuling
- Subjects
- *
LIQUID chromatography-mass spectrometry , *METABOLITES , *BLOOD plasma , *LABORATORY rats , *ELECTROSPRAY ionization mass spectrometry , *ANTINEOPLASTIC agents , *ALKALOIDS - Abstract
CAT ((+)-(13aS)-deoxytylophorinine) is a novel anticancer drug belonging to phenanthroindolizidine alkaloids. A sensitive and reliable liquid chromatography–tandem mass spectrometry (LC–MS/MS) method for simultaneous quantification of CAT and its pharmacologically active 3-O-desmethyl metabolite (S-4) was developed and validated in rat plasma using rotundine as the internal standard (IS). CAT, S-4 and IS were extracted by acetonitrile protein precipitation and separated on an Eclipse XDB-C18 column (1.8 μm, 4.6 mm × 50 mm) with acetonitrile–water (27:73, v/v) mobile phase containing 0.1% formic acid at a 0.4 mL/min flow rate. Positive ion electrospray ionization in multiple reaction monitoring mode was employed to measure CAT, S-4 and IS by monitoring the transitions m/z 364.2 → 70.1 for CAT, 350.1 → 70.1 for S-4 and 356.2 → 192.2 for IS. Good linear correlation ( r 2 > 0.991) was achieved for CAT and S-4 over the range of 0.214–128.16 and 0.044–11.00 ng/mL, respectively. The lower limit of quantification was 0.214 ng/mL for CAT and 0.044 ng/mL for S-4, using 50 μL rat plasma samples. The intra- and inter-day precisions were not exceed 15% and the accuracy ranged between 94.80% and 108.22%. The average extraction recoveries of both analytes were greater than 94.62%. The method was successfully applied to the pharmacokinetic study of CAT and S-4 in rats after oral administration. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. An LC-MS/MS method for the quantitation of cabozantinib in rat plasma: Application to a pharmacokinetic study.
- Author
-
Su, Qinghong, Li, Jian, Ji, Xiwei, Li, Jingyun, Zhou, Tianyan, Lu, Wei, and Li, Liang
- Subjects
- *
PROTEIN-tyrosine kinase inhibitors , *LIQUID chromatography-mass spectrometry , *PHARMACOKINETICS , *ERLOTINIB , *LIQUID-liquid extraction , *LABORATORY rats - Abstract
A simple, rapid and sensitive high-performance liquid chromatography tandem mass-spectrometric method (LC-MS/MS) for the novel multiple tyrosine kinase inhibitor (TKI) cabozantinib was developed and validated using erlotinib as internal standard (IS). Plasma samples were pre-treated by liquid–liquid extraction with ethyl acetate. Separation was achieved on a reversed phase C18 column (50 × 2 mm, 5 μm) at ambient temperature using isocratic elution with acetonitrile-water (45:55, v/v) containing 5 mM ammonium formate buffer (finally adjusted to apparent pH* = 5.0 with formic acid) at a flow rate of 0.4 mL/min. The analytes were monitored by a triple quadrupole tandem mass spectrometer with electrospray ionization source in the positive ion mode. Calibration curve was linear ( r > 0.99) in a concentration range of 0.5–1000 ng/mL with the lower limit of quantification (LLOQ) of 0.5 ng/mL. Intra- and inter-day accuracy and precision were validated by relative error values (RE) and relative standard deviation values (RSD), respectively, which were both lower than the limit of 15%. This method was successfully applied to a pharmacokinetic study of cabozantinib in rats. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. Development and validation of liquid chromatography–tandem mass spectrometry method for quantification of a potential anticancer triterpene saponin from seeds of Nigella glandulifera in rat plasma: Application to a pharmacokinetic study.
- Author
-
Hu, Xingjiang, Liu, Xiaobao, Gong, Minghua, Luan, Ming, Zheng, Yunliang, Wu, Guolan, Shentu, Jianzhong, and Zhang, Lin
- Subjects
- *
LIQUID chromatography-mass spectrometry , *ANTINEOPLASTIC agents , *TRITERPENES , *BLOOD plasma , *PHARMACOKINETICS , *RANUNCULACEAE , *LABORATORY rats - Abstract
Nigella glandulifera Freyn et Sit is a folk medicinal plant, whose seeds show significant anticancer activities attributed to triterpene saponins and volatile oil. In this study, an in vitro cytotoxicity assay demonstrated that Nigella A, the major component of triterpene saponins extracted from N. glandulifera , exhibited growth inhibition in the human lung carcinoma A-549 cell line. Due to this potential activity, a reliable liquid chromatography–tandem mass spectrometry (LC–MS/MS) method to quantify Nigella A in rat plasma for a pharmacokinetic study was developed. Nigella A and pravastatin, as internal standard (IS), were extracted from rat plasma using acetonitrile to precipitate protein. Separation was performed on an Agilent Zorbax SB-Aq (3.0 × 150 mm, 3.5 μm) column using a gradient elution method with acetonitrile–0.1% formic acid in water at a flow rate of 0.35 mL/min. Detection was performed using an electrospray ionization in a negative ion multiple reaction monitoring mode. The deprotonated precursor to product ion transitions monitored for Nigella A and IS was at m / z 1352.7→882.6 and m / z 423.1→321.0, respectively. The linear range was 0.240–120 μg/mL with a square regression coefficient ( r = 0.9996). The intra-day and inter-day precision was less than 6.93%. The simple extraction procedure provided recovery ranged from 92.32 to 95.44% for both analyte and IS. The method was proved to be reliable, precise, and accurate, and was successfully applied to a pharmacokinetic study of Nigella A in rats after i.v. administration via the tail vein at doses of 10, 20, and 30 mg/kg. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Simultaneous determination of 7-O-succinyl macrolactin A and its metabolite macrolactin A in rat plasma using liquid chromatography coupled to tandem mass spectrometry.
- Author
-
Keumhan Noh, Dong Hee Kim, Beom Soo Shin, Hwi-yeol Yun, Eunyoung Kim, and Wonku Kang
- Subjects
- *
ANTIBACTERIAL agents , *LABORATORY rats , *BLOOD plasma , *LIQUID chromatography-mass spectrometry , *CANCER cells , *BACILLUS (Bacteria) , *NEOVASCULARIZATION inhibitors - Abstract
7-O-Succinyl macrolactin A (SMA) and its major metabolite macrolactin A (MA) are generated from Bacillus polyfermenticus KJS-2. Both substances show inhibitory effects on angiogenesis and cancer cell invasion. SMA in rat plasma is known to be relatively stable at room temperature, but MA was not detected due to its instability. Therefore, a stabilizer is required to accurately measure the substance in biological rat samples. In this study, NaF and eserine were examined to determine whether they could stabilize MA to allow for accurate measurement in rat plasma. We also developed a rapid and simple chromatographic method using tandem mass spectrometry (MS/MS) for the simultaneous determination of these compounds in rat plasma. After simple protein precipitation with acetonitrile including methaqualone (internal standard), the analytes were chromatographed on a Hilic column with a mobile phase of 10 mM formic acid aqueous solution, methanol, and acetonitrile (15:15:70, v/v). The accuracy and precision of the assay were in accordance with FDA regulations for the validation of bioanalytical methods. This analytical method was successfully applied to monitor plasma concentrations of both compounds over time following intravenous administration of a salt form of SMA in rats. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: Application to a pharmacokinetic study.
- Author
-
Wenwen Sui, Xiaojing Yang, Wenhong Yu, Yi Jin, Xinyi Luan, Xiangjun Wang, and Haiyan Xu
- Subjects
- *
LIQUID chromatography-mass spectrometry , *ANTIDEPRESSANTS , *BLOOD plasma , *PHARMACOKINETICS , *LABORATORY rats , *ESCITALOPRAM - Abstract
A rapid and sensitive LC-MS/MS method was developed for the quantification of vilazodone in rat plasma using escitalopram as internal standard. After extracted with organic solvent, post-treatment samples were chromatographed on an Agela C18 column. An isocratic mobile phase of acetonitrile: 5 mM ammonium acetate: formic acid (35:65:0.1, v/v/v) was applied at a flow rate of 0.25 mL/min. Detection was performed using multiple reaction-monitoring (MRM) modes at m/z 442.4 → 155.3 for vilazodone and m/z 325.1 → 109.0 for escitalopram. The method was linear in the concentration range of 1.0 - 100 ng/mL with a correlation coefficient ≥0.993. The intra- and inter-assay precision (%RSD) values were within 13.4%, and intra- and inter-day accuracy (%RE) ranged from -9.8 to 6.9%. The total analysis time was 2.2 min. The LC-MS/MS method was fully validated for its sensitivity, selectivity, stability, matrix effect and recovery. The data indicated that the developed method was rapid, specific and sensitive. This method was further and successfully applied in the pharmacokinetics study of vilazodone in rat. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.